Stockscreener 앱 받기
32.41
14.89%
4.20
시간 외 거래:
31.85
-0.56
-1.73%
Roivant Sciences Ltd 주식(ROIV)의 최신 뉴스
Roivant Sciences stock hits all-time high of 30.35 USD By Investing.com - Investing.com Canada
Roivant Sciences earnings beat by $0.57, revenue fell short of estimates - Investing.com India
Why is Roivant Sciences stock surging today? By Investing.com - Investing.com South Africa
ROIV: High efficacy in refractory RA, strong cash, and major launches expected in the coming year - TradingView
Roivant Sciences (ROIV) Surges 14.8% to $32.38 - AlphaStreet
Roivant Sciences Shares Jump 14.43% to $32.28 on Strong IMVT-1402 Rheumatoid Arthritis Data - International Business Times Australia
Roivant Sciences Ltd. Reports Earnings Results for the Fourth Quarter Ended March 31, 2026 - marketscreener.com
Roivant gains after mid-stage trial data for Immunovant’s main asset - Seeking Alpha
Roivant Sciences Q4 Earnings Call Highlights - inkl
Immunovant Q4 Earnings Call Highlights - inkl
TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Movin - Benzinga
Roivant Sciences stock hits all-time high of 30.35 USD - Investing.com
Roivant Sciences Ltd reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: Roivant Sciences surprises with Q4 2026 EPS beat - Investing.com Canada
Roivant Sciences Reports Q4 2026 Results: Full Earnings Call Transcript - Benzinga
Roivant Shares Climb on Earnings Beat Despite Revenue Shortfall (ROIV) - Yahoo Finance
Roivant Sciences : Financial Results and Business Updates for the Year Ended March 31 2026 - marketscreener.com
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
ROIV: Strong clinical progress, major litigation win, and robust cash position set up multiple 2027 catalysts - TradingView
Roivant Sciences Ltd. Reports FY2025 Financial Results and Key Developments in May 2026 - Minichart
Roivant shares jump 10% on earnings beat despite revenue miss By Investing.com - Investing.com Australia
Roivant Sciences Ltd. 2026 Annual Report: Business Overview, Risk Factors, and Product Pipeline Highlights - Minichart
Roivant shares jump 10% on earnings beat despite revenue miss - Investing.com
Roivant Sciences Ltd. FY 2026: Revenue $8.26M, EPS ($0.54) — 10-K Summary - TradingView
Roivant Reports $355.7M Q4 Income from Continuing Ops, $4.3B Cash Position - TradingView
Earnings Flash (ROIV) Roivant Posts Fiscal Q4 EPS From Continuing Operations $0.28 - marketscreener.com
Roivant (ROIV) touts late-stage pipeline and Genevant’s $2.25B Moderna IP deal - Stock Titan
Earnings Flash (ROIV) Roivant Sciences Ltd. Reports Q4 Revenue $2.5M, vs. FactSet Est of $3.4M - marketscreener.com
Roivant (NASDAQ: ROIV) books $770M legal gain and holds $4.3B cash - Stock Titan
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update - The Manila Times
Roivant Sciences Ltd. (ROIV) Tops Q4 EPS by 57c - StreetInsider
Roivant Sciences Ltd. Stock 12‑Month Price Target Raised to $36.23, Implies 28% Upside - TradingView
How The Roivant Sciences (ROIV) Story Is Shifting After Settlements And Brepocitinib Milestones - Yahoo Finance
Roivant Sciences Q4 2026 earnings preview - MSN
Montes Archimedes Acquisition (ROIV) Upgraded to Buy: Here's Why - sharewise.com
A Look At Roivant Sciences (ROIV) Valuation As IMVT-1402 And Earnings Outlook Draw Investor Focus - simplywall.st
Roivant in the spotlight as earnings loom with approval ahead By Investing.com - Investing.com Australia
Roivant in the spotlight as earnings loom with approval ahead - Investing.com India
Myasthenia Gravis Market Set to Surpass USD 16 Billion by 2036, Fueled by Rising Diagnosed Prevalence and Wave of Targeted Biologic Approvals | DelveInsight - GlobeNewswire Inc.
Book value per share of Roivant Sciences Ltd. – LSX:A3C4MS - TradingView
Roivant Sciences Q4 2026 Earnings Preview — May 20, Street Expects -$0.35 EPS - AlphaStreet
Trading the Move, Not the Narrative: (ROIV) Edition - Stock Traders Daily
Earnings Preview: ROIV to Report Financial Results Pre-market on May 20 - Moomoo
ROIVANT SCIENCES LTD (NASDAQ:ROIV) Flashes Strong Breakout Setup with Near-Perfect Technical and Setup Quality Ratings - ChartMill
TradingKey - TradingKey
ROIV Q4'25 Earnings: revenue estimate is 3.41M USD - TradingView
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026 - marketscreener.com
Roivant Sciences Ltd. (ROIV) Stock Analysis: Exploring a 24.88% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
ROIV Stock Price, Quote & Chart | ROIVANT SCIENCES LTD (NASDAQ:ROIV) - ChartMill
Insiders At Roivant Sciences Sold US$112m In Stock, Alluding To Potential Weakness - Moomoo
Roivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
A Look At Roivant Sciences (ROIV) Valuation After Encouraging Phase 2 Brepocitinib Data - Yahoo Finance
Baron Fund Puts Spotlight On Roivant’s Brepocitinib And Valuation Gap - simplywall.st
Assessing Roivant Sciences (ROIV) Valuation After Strong 1-Year Return And Recent Share Price Momentum - simplywall.st
Who is Vivek Ramaswamy, 2026 Republican nominee for Ohio governor? - marketscreener.com
MSN Money - MSN
Baron Health Care Fund Reports Roivant Sciences as Top Q1 2026 Performer - HarianBasis.co
Here’s Why Roivant Sciences Ltd (ROIV) Rallied in Q1 - Insider Monkey
(ROIV) Volatility Zones as Tactical Triggers - Stock Traders Daily
Roivant Sciences Ltd. (ROIV) Stock Analysis: A 28% Upside In Biotech Innovation - DirectorsTalk Interviews
How New Analyst Coverage Spotlighting Brepocitinib’s Phase 3 Readouts At Roivant Sciences (ROIV) Has Changed Its Investment Story - simplywall.st
Vanguard Group Inc. Has $912.68 Million Stock Position in Roivant Sciences Ltd. $ROIV - MarketBeat
0.47%
자본화:
|
볼륨(24시간):